La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Vaxxinity Bilan de santé

Santé financière contrôle des critères 3/6

Vaxxinity possède un total de capitaux propres de $13.4M et une dette totale de $15.2M, ce qui porte son ratio d'endettement à 113.1%. Son actif total et son passif total sont $44.3M et de $30.9M.

Informations clés

113.1%

Ratio d'endettement

US$15.17m

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$30.64m
Fonds propres	US$13.41m
Total du passif	US$30.90m
Total des actifs	US$44.31m

Mises à jour récentes de la santé financière

Recent updates

A Look At The Intrinsic Value Of Vaxxinity, Inc. (NASDAQ:VAXX)

Jan 08

Vaxxinity initiates rolling submission for its COVID-19 shot with UK's drug regulator

Sep 12

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de VAXX ( $33.2M ) dépassent ses passifs à court terme ( $17.6M ).

Passif à long terme: Les actifs à court terme de VAXX ( $33.2M ) dépassent ses passifs à long terme ( $13.3M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: VAXX dispose de plus de liquidités que de sa dette totale.

Réduire la dette: Données insuffisantes pour déterminer si le ratio d'endettement de VAXX a diminué au cours des 5 dernières années.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: VAXX dispose de moins d'un an de piste de trésorerie sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: VAXX dispose de moins d'un an de marge de trésorerie si le flux de trésorerie disponible continue de diminuer à un taux historique de 10.5 % chaque année

Vaxxinity Bilan de santé

Santé financière contrôle des critères 3/6

Informations clés

Mises à jour récentes de la santé financière

Vaxxinity Files Form 15

Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock

Vaxxinity, Inc. Receives A Notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC

Recent updates

Vaxxinity UB-312 Parkinson’s Trial Results Published in Nature Medicine

Vaxxinity Files Form 15

Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock

Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024

Vaxxinity, Inc. Receives A Notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC

Vaxxinity, Inc. Announces the Publication of Data from Multiple Non-Human Primate Studies

Vaxxinity, Inc. to Present Data from UB-312 Program in Parkinson's Disease at International Conference on Alzheimer's and Parkinson's Diseases and Related Neurolog Disorders

New major risk - Revenue and earnings growth

New minor risk - Market cap size

Vaxxinity, Inc. Announces Resignation of Katherine Eade from the Board of Directors

New major risk - Financial position

High number of new directors

Vaxxinity, Inc. Announces Executive Changes

Vaxxinity, Inc. Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer's Disease

New minor risk - Financial position

Vaxxinity, Inc. Announces Executive Changes

Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson's Disease

Non-Employee Independent Director exercised options to buy US$1.0m worth of stock.

Less than half of directors are independent

Vaxxinity, Inc. Announces the Relocation of its Corporate Headquarters

A Look At The Intrinsic Value Of Vaxxinity, Inc. (NASDAQ:VAXX)

Vaxxinity Announces Positive Topline Pivotal Phase 3 COVID-19 Booster Data for UB-612

Price target decreased to US$13.50

Less than half of directors are independent

Price target decreased to US$13.50

Vaxxinity Completes Enrollment in Pivotal Phase 3 Clinical Trial of UB-612 COVID-19 Vaccine Heterologous Booster Candidate and Initiates Rolling Submission for Provisional Approval in Australia

Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of UB-313 for Preventive Treatment of Migraine

Vaxxinity initiates rolling submission for its COVID-19 shot with UK's drug regulator

Vaxxinity's Anti-PCSK9 Candidate Demonstrates Durable LDL Cholesterol Lowering in Non Human Primates

Vaxxinity, Inc. Presents Preclinical Data on Tau Vaccine Candidates At the 2022 Alzheimer's Association International Conference

Less than half of directors are independent

The Coalition for Epidemic Preparedness Innovations to Co-Fund Vaxxinity, Inc.'s Pivotal Phase 3 UB-612 Heterologous Booster Trial to Combat SARS-CoV-2 variants

Less than half of directors are independent

Vaxxinity, Inc. Announces First Participant Dosed in Phase 3 Study of Next-Generation Covid-19 Vaccine Booster

Vaxxinity’s COVID-19 Vaccine Candidate UB-612 Produces High Levels of Neutralizing Antibodies Against Omicron and Other Variants of Concern

Vaxxinity, Inc. Announces First Parkinson’s Disease Patient Dosed in Part B of Phase 1 Clinical Trial of UB-312

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Non-Employee Independent Director recently bought US$63k worth of stock

Co-Founder & Executive Chairman recently bought US$242k worth of stock

Less than half of directors are independent

Second quarter 2021 earnings released: US$0.39 loss per share

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines